As a new concept of glioma therapy, immunotherapy combined with standard therapies is a promising modality to improve glioma patient survival. VEGF and its signaling pathway molecules not only inhibit angiogenesis but also may reinforce the immunosuppressive tumor microenvironment, including promotion of the accumulation of immunosuppressive tumor-associated macrophages (TAMs). In this review, we discuss VEGF-targeted therapy as a new treatment option of the TAM-targeted therapy for high-grade gliomas, as well as other TAM-targeted therapies. The authors also discuss the potential of these therapies combined with conventional immunotherapies.

中文翻译：

---

胶质瘤免疫治疗的抗血管生成和基于巨噬细胞的治疗策略

作为胶质瘤治疗的一个新概念，免疫疗法结合标准疗法是提高胶质瘤患者生存率的一种有前景的方式。VEGF及其信号通路分子不仅可以抑制血管生成，还可以增强免疫抑制性肿瘤微环境，包括促进免疫抑制性肿瘤相关巨噬细胞（TAMs）的积累。在这篇综述中，我们讨论了 VEGF 靶向治疗作为 TAM 靶向治疗高级别胶质瘤的新治疗选择，以及其他 TAM 靶向治疗。作者还讨论了这些疗法与传统免疫疗法相结合的潜力。